Stocks Health care NKTR
NASDAQ · Health careNektar Therapeutics (NKTR)
Nektar Therapeutics brought in $54.6M of revenue over the twelve months to June 30, 2026, down 27.2% from a year earlier. It posted a net loss of $157.1M. In fiscal 2025 capital spending exceeded operating cash flow by $208.7M. At June 30, 2026 it held $39.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Nektar Therapeutics
- Net worth
- Nektar Therapeutics has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $903.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $55.2M (-43.9% year on year), with a net loss of $164.1M. Over the 12 months to June 30, 2026: revenue $54.6M, net loss $157.1M.
- Cash flow
- In fiscal 2025 operations used $208.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Nektar Therapeutics's next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Nektar Therapeutics does
Nektar Therapeutics is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NKTR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $55.2M | -$164.1M | -$9.73 | -$208.7M |
| 2024 | $98.4M | -$119M | -$8.68 | -$177.2M |
| 2023 | $90.1M | -$276.1M | -$21.70 | -$193.5M |
| 2022 | $92.1M | -$368.2M | -$29.48 | -$309.7M |
| 2021 | $101.9M | -$523.8M | -$42.80 | -$427.6M |
| 2020 | $152.9M | -$444.4M | -$37.26 | -$320.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NKTR ranks in Health care
Latest SEC filings
What Nektar Therapeutics has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 20, 2026
- October 1, 2026
- September 28, 2026Passive stake changed SCHEDULE 13G/A
- September 25, 2026Other event 8-K
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 9.3% to $10.1M versus the same quarter last year; diluted EPS -$1.23 versus -$2.95.
- August 13, 2026
Insider trades
What the people running Nektar Therapeutics did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $43.5K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 23, 2026 | Ajer Jeffrey RobertDirector | Received as pay | 2,000 | - |
| September 23, 2026 | Brainard DianaDirector | Received as pay | 2,000 | - |
| September 23, 2026 | Chess RobertDirector | Received as pay | 2,000 | - |
| September 23, 2026 | Greer R ScottDirector | Received as pay | 2,000 | - |
| September 23, 2026 | Whitfield Roy ADirector | Received as pay | 2,000 | - |
| August 18, 2026 | Robin Howard WPresident & CEO, Director | Sold | 418 | $30.1K |
| August 18, 2026 | Zalevsky JonathanChief R&D Officer | Sold | 186 | $13.4K |
| June 30, 2026 | Zalevsky JonathanChief R&D Officer | Soldpre-planned (10b5-1) | 5,681 | $397.7K |
Who owns NKTR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | May 6, 2026 |
| Two Seas Capital LP13G, passive with 2 related filers | 9.8% | September 28, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 7.1% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.17% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 240 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 5,067,920 | +764,732 |
| Two Seas Capital LP | 3,092,234 | +1,133,056 |
| BlackRock, Inc. | 2,941,851 | +2,249,201 |
| Bvf Inc | 2,391,075 | -168,520 |
| Vanguard Capital Management LLC | 1,496,849 | +299,794 |
| Two Sigma Investments, LP | 1,202,004 | +271,263 |
| Vestal Point Capital, LP | 1,000,000 | +715,000 |
| Morgan Stanley | 936,560 | +277,173 |
| State Street Corp | 909,679 | +664,952 |
| Geode Capital Management, LLC | 881,306 | +534,511 |
| Prosight Management, LP | 810,000 | +75,000 |
| Armistice Capital, LLC | 724,000 | +146,000 |
| Gilder Gagnon Howe & Co LLC | 600,873 | +329,115 |
| Millennium Management LLC | 478,120 | +73,843 |
| Braidwell LP | 473,617 | +250,916 |
| Sofinnova Investments, Inc. | 471,763 | -37,783 |
| Woodline Partners LP | 470,875 | +55,540 |
| Orbimed Advisors LLC | 465,346 | +190,346 |
| UBS Group AG | 428,400 | +108,228 |
| Emerald Advisers, LLC | 390,158 | -4,446 |
Insiders
8 insiders reported holding 151,638 shares in total, about $5.7M at the last price.
| Holder | Shares |
|---|---|
| Robin Howard WPresident & CEO, Director | 54,627 |
| Greer R ScottDirector | 22,239 |
| Wilson Mark AndrewChief Legal Officer | 21,585 |
| Chess RobertDirector | 19,019 |
| Whitfield Roy ADirector | 16,417 |
| Zalevsky JonathanChief R&D Officer | 9,570 |
| Ajer Jeffrey RobertDirector | 4,277 |
| Brainard DianaDirector | 3,904 |
Questions about NKTR
What does Nektar Therapeutics do?
Nektar Therapeutics is a company in the Health care sector, listed on NASDAQ as NKTR. Its shares trade on NASDAQ under the ticker NKTR.
What is Nektar Therapeutics's net worth?
Nektar Therapeutics has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $903.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nektar Therapeutics profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $157.1M on revenue of $54.6M.
How much revenue does Nektar Therapeutics make?
Over the twelve months to June 30, 2026 Nektar Therapeutics reported revenue of $54.6M. That is 27.2% less than a year earlier.
When did Nektar Therapeutics last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from October 20, 2026.
When is Nektar Therapeutics's next earnings report?
Nektar Therapeutics's next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare NKTR with
Follow NKTR
Get an email when Nektar Therapeutics files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nektar Therapeutics tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.